Methods: We investigated the prognostic impact of the KIR2DL5B genotype in 240 CML patients included in two clinical trials investigating tyrosine kinase inhibitors (TKI) discontinuation: STIM and STIM2. Here, STIM2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.